Lundbeck Seattle BioPharmaceuticals, Inc.
BiotechLundbeck Seattle BioPharmaceuticals, Inc. is a biotechnology company focused on Neurology.
Lundbeck Seattle BioPharmaceuticals, Inc.'s Key Drugs
Lundbeck Seattle BioPharmaceuticals, Inc.'s core commercial portfolio centers on VYEPTI, spanning Neurology — its most strategically important drugs approved in the last 15 years.
Lundbeck Seattle BioPharmaceuticals, Inc.'s Recent FDA Approvals
New NDA/BLA approvals for Lundbeck Seattle BioPharmaceuticals, Inc. over the last two years — novel drugs only, excluding generics and label supplements.
Lundbeck Seattle BioPharmaceuticals, Inc.'s Therapeutic Areas
Lundbeck Seattle BioPharmaceuticals, Inc.'s approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Lundbeck Seattle BioPharmaceuticals, Inc.'s Top Competitors
Lundbeck Seattle BioPharmaceuticals, Inc.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Lundbeck Seattle BioPharmaceuticals, Inc. Pipeline Snapshot
Active clinical trials for Lundbeck Seattle BioPharmaceuticals, Inc. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VYEPTI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-02-21
- Latest
- 2026-06-05
- Applications
- 1